Literature DB >> 29407767

Involvement of glycine receptor α1 subunits in cannabinoid-induced analgesia.

Jieping Lu1, Sijia Fan2, Guichang Zou2, Yiwen Hou2, Tao Pan3, Weiwei Guo2, Lei Yao2, Feng Du2, Gregg E Homanics4, Dan Liu5, Li Zhang6, Wei Xiong7.   

Abstract

Some cannabinoids have been shown to suppress chronic pain by targeting glycine receptors (GlyRs). Although cannabinoid potentiation of α3 GlyRs is thought to contribute to cannabinoid-induced analgesia, the role of cannabinoid potentiation of α1 GlyRs in cannabinoid suppression of chronic pain remains unclear. Here we report that dehydroxylcannabidiol (DH-CBD), a nonpsychoactive cannabinoid, significantly suppresses chronic inflammatory pain caused by noxious heat stimulation. This effect may involve spinal α1 GlyRs since the expression level of α1 subunits in the spinal cord is positively correlated with CFA-induced inflammatory pain and the GlyRs antagonist strychnine blocks the DH-CBD-induced analgesia. A point-mutation of S296A in TM3 of α1 GlyRs significantly inhibits DH-CBD potentiation of glycine currents (IGly) in HEK-293 cells and neurons in lamina I-II of spinal cord slices. To explore the in vivo consequence of DH-CBD potentiation of α1 GlyRs, we generated a GlyRα1S296A knock-in mouse line. We observed that DH-CBD-induced potentiation of IGly and analgesia for inflammatory pain was absent in GlyRα1S296A knock-in mice. These findings suggest that spinal α1 GlyR is a potential target for cannabinoid analgesia in chronic inflammatory pain.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Analgesia; Cannabinoid; Glycine receptor; Inflammatory pain; Potentiation

Mesh:

Substances:

Year:  2018        PMID: 29407767     DOI: 10.1016/j.neuropharm.2018.01.041

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Neuromolecular Mechanisms of Cannabis Action.

Authors:  Yousra Adel; Stephen P H Alexander
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Cannabidiol for the treatment of autism spectrum disorder: hope or hype?

Authors:  João F C Pedrazzi; Frederico R Ferreira; Danyelle Silva-Amaral; Daniel A Lima; Jaime E C Hallak; Antônio W Zuardi; Elaine A Del-Bel; Francisco S Guimarães; Karla C M Costa; Alline C Campos; Ana C S Crippa; José A S Crippa
Journal:  Psychopharmacology (Berl)       Date:  2022-07-29       Impact factor: 4.415

3.  Combined alcohol and cannabinoid exposure leads to synergistic toxicity by affecting cerebellar Purkinje cells.

Authors:  Guichang Zou; Jing Xia; Heyi Luo; Dan Xiao; Jin Jin; Chenjian Miao; Xin Zuo; Qianqian Gao; Zhi Zhang; Tian Xue; Yezi You; Ye Zhang; Li Zhang; Wei Xiong
Journal:  Nat Metab       Date:  2022-09-15

4.  The synthetic cannabinoid dehydroxylcannabidiol restores the function of a major GABAA receptor isoform in a cell model of hyperekplexia.

Authors:  Guichang Zou; Jing Xia; Qianqian Han; Dan Liu; Wei Xiong
Journal:  J Biol Chem       Date:  2019-11-22       Impact factor: 5.157

5.  Membrane cholesterol dependence of cannabinoid modulation of glycine receptor.

Authors:  Lei Yao; Marta Wells; Xiongwu Wu; Yan Xu; Li Zhang; Wei Xiong
Journal:  FASEB J       Date:  2020-07-01       Impact factor: 5.834

6.  A System for Assessing Dual Action Modulators of Glycine Transporters and Glycine Receptors.

Authors:  Diba Sheipouri; Casey I Gallagher; Susan Shimmon; Tristan Rawling; Robert J Vandenberg
Journal:  Biomolecules       Date:  2020-11-30

7.  Structural basis for cannabinoid-induced potentiation of alpha1-glycine receptors in lipid nanodiscs.

Authors:  Arvind Kumar; Kayla Kindig; Shanlin Rao; Afroditi-Maria Zaki; Sandip Basak; Mark S P Sansom; Philip C Biggin; Sudha Chakrapani
Journal:  Nat Commun       Date:  2022-08-18       Impact factor: 17.694

Review 8.  Novel approaches and current challenges with targeting the endocannabinoid system.

Authors:  Paula Morales; Nadine Jagerovic
Journal:  Expert Opin Drug Discov       Date:  2020-04-27       Impact factor: 7.050

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.